United Capital Financial Advisors LLC Has $246,000 Stake in Baxter International Inc. (NYSE:BAX)

United Capital Financial Advisors LLC decreased its position in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 53.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,440 shares of the medical instruments supplier's stock after selling 9,579 shares during the quarter. United Capital Financial Advisors LLC's holdings in Baxter International were worth $246,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Gabelli Funds LLC raised its holdings in Baxter International by 6.9% during the 4th quarter. Gabelli Funds LLC now owns 329,200 shares of the medical instruments supplier's stock worth $9,599,000 after purchasing an additional 21,200 shares during the last quarter. Dodge & Cox raised its position in shares of Baxter International by 13.0% during the 4th quarter. Dodge & Cox now owns 50,377,294 shares of the medical instruments supplier's stock valued at $1,469,002,000 after acquiring an additional 5,779,100 shares during the last quarter. Jump Financial LLC boosted its position in shares of Baxter International by 1,078.2% in the 4th quarter. Jump Financial LLC now owns 139,028 shares of the medical instruments supplier's stock worth $4,054,000 after purchasing an additional 127,228 shares during the last quarter. Anchor Investment Management LLC increased its holdings in Baxter International by 79.2% in the fourth quarter. Anchor Investment Management LLC now owns 20,463 shares of the medical instruments supplier's stock valued at $597,000 after purchasing an additional 9,043 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its holdings in Baxter International by 55.2% during the fourth quarter. Sterling Capital Management LLC now owns 30,264 shares of the medical instruments supplier's stock worth $882,000 after buying an additional 10,768 shares during the last quarter. 90.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BAX has been the subject of several recent analyst reports. The Goldman Sachs Group started coverage on shares of Baxter International in a research note on Wednesday, February 26th. They issued a "buy" rating and a $42.00 target price for the company. Barclays raised their price target on Baxter International from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Monday, March 10th. Argus raised Baxter International from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Baxter International from $38.00 to $36.00 and set a "neutral" rating for the company in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Baxter International currently has a consensus rating of "Hold" and an average price target of $38.56.

Baxter International Stock Down 1.1 %

NYSE:BAX opened at $28.56 on Tuesday. The firm has a market capitalization of $14.65 billion, a price-to-earnings ratio of -22.31, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. Baxter International Inc. has a twelve month low of $26.25 and a twelve month high of $41.18. The stock's 50 day moving average price is $32.45 and its two-hundred day moving average price is $32.56.

Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The firm had revenue of $2.75 billion during the quarter, compared to analysts' expectations of $2.67 billion. Equities research analysts expect that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th were paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.38%. The ex-dividend date was Friday, February 28th. Baxter International's dividend payout ratio is presently -53.13%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.